MRD & Disease Monitoring Archives

September 13, 2022

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed MRD as a biomarker to direct treatment duration in a phase 2 clinical trial of

September 1, 2022

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

We discuss the latest results from the GLOW study, a phase 3 clinical trial which compared fixed-duration ibrutinib + venetoclax with chemoimmunotherapy (chlorambucil + obinutuzumab) as a first-line treatment.

September 1, 2022

ASH 2021: High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Various combinations of venetoclax plus other agents such as venetoclax plus rituximab (RVe), venetoclax and obinutuzumab (GVe), or venetoclax plus rituximab plus obinutuzumab (GIVe) provide fixed duration treatment options with high rates of success.

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

November 22, 2021

Achieving Innovation in CLL Care Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

Join CLL Society and PeerView Institute to watch the ASH 2021 Symposium about the newest data on BTK inhibitors and CAR-T cell constructs in CLL Treatment.

June 24, 2021

ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for Chronic Lymphocytic Leukemia (CLL)

The team at Dana-Farber Cancer Institute is testing whether the combination of duvelisib (Copiktra™) and venetoclax (Venclexta®) will lead to deep remissions that would allow for oral only therapy of one year duration. Learn more about this ongoing Phase I/II clinical trial.

June 24, 2021

ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL)

The treatment landscape for those of us with CLL/SLL has changed dramatically in the past decade or less. We see decreasing reliance on chemoimmunotherapies that were the only option in the past. We have seen a move from sequential use of targeted therapies to control our CLL to combinations

June 17, 2021

ASH 2020: Dr. Paolo Ghia on the Benefits of Individualized Treatment Plans for Chronic Lymphocytic Leukemia (CLL)

At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Paolo Ghia, Director of the Strategic Research Program on CLL at Università Vita-Salute San Raffaele in Milan, Italy. They discussed results from a clinical trial which individually tailored treatment plans

June 2, 2021

ASH 2020: Dr. Jennifer Woyach on Triple Combination Therapy for Chronic Lymphocytic Leukemia (CLL)

Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib have been wonderfully effective drugs for treating chronic lymphocytic leukemia (CLL). However, on their own they must be taken continuously and do not produce deep enough remissions to warrant stopping treatment.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

MRD & Disease Monitoring

ASH 2021: Dr. Jake Soumerai on Measurable Residual Disease-Guided Treatment of Chronic Lymphocytic Leukemia (CLL) with Venetoclax and Obinutuzumab plus Zanubrutinib

ASH 2021: Dr. Talha Munir on Measurable Residual Disease After Fixed-Duration Ibrutinib plus Venetoclax

ASH 2021: High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

Achieving Innovation in CLL Care Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

ASH 2020: Dr. Davids Discusses Duvelisib and Venetoclax, an All-Oral Time-Limited Treatment for Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Furman Discusses Minimal Residual Disease-Driven Captivate and Murano Studies in Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Paolo Ghia on the Benefits of Individualized Treatment Plans for Chronic Lymphocytic Leukemia (CLL)

ASH 2020: Dr. Jennifer Woyach on Triple Combination Therapy for Chronic Lymphocytic Leukemia (CLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT